Navigation Links
5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
Date:2/20/2008

MENLO PARK, Calif., Feb. 20 /PRNewswire/ -- 5AM Ventures, specializing in seed and early-stage investments in next-generation life science companies, today announced the expansion of the firm's investment team with the appointment of Richard Ulevitch, PhD, as Venture Partner. 5AM Ventures also announced the promotion of two of the firm's senior associates, Kevin M. Forrest, PhD, and R. Andrew McMillan, PhD, to Principal. Drs. Forrest and McMillan have been with the 5AM team since early 2005. Carin M. Rollins, a founder and formerly a Principal has transitioned to a consulting role with the firm.

Dr. Ulevitch joins 5AM Ventures from The Scripps Research Institute (Scripps). He is a renowned expert in the field of immunology; his research has contributed to the discovery of breakthrough therapeutic product candidates targeting the immune system. In addition to serving as Chair of the Department of Immunology at Scripps since 1994, he has been Chairman of 5AM Ventures' Scientific Advisory Board since the firm was founded in 2002. As Venture Partner, Dr. Ulevitch will identify and review new investment opportunities as well as continue working with the firm's existing portfolio companies.

"A distinguished academic researcher who has made significant contributions to the field of immunology as well as a long-time advisor to biotechnology companies and investment funds, Richard Ulevitch brings tremendous insight into the critical evaluation of important new investment opportunities. We are very pleased to add Richard's expertise on the translation of scientific discoveries into therapeutic products, which will make him an invaluable advisor to the firm and resource to our portfolio companies," said John D. Diekman, PhD, Managing Partner of 5AM Ventures.

"We are pleased to recognize the accomplishments of the 5AM team through the promotion of Drs. Kevin Forrest and Andrew McMillan. Kevin and Andrew provide our firm with a strong blend of scientific insights and business acumen essential to evaluating future investments and managing the success of 5AM's life science company portfolio," said Scott M. Rocklage, PhD, Managing Partner of 5AM Ventures.

For nearly three decades, Dr. Ulevitch's pioneering research has contributed to the identification and understanding of the basic mechanisms of human innate immune response to infection. His discoveries have and are currently being translated into drug development in the areas of acute and chronic inflammation and septic shock. In addition to his scientific achievements, Dr. Ulevitch has been affiliated with scientific advisory panels for the National Institutes of Health, the American Heart Association, and the U.S. Food and Drug Administration (FDA). He has also served as a scientific advisor to Lombard Odier Immunology Fund (Geneva) and Aravis Ventures (Zurich), and a consultant to numerous biotechnology and pharmaceutical companies. Dr. Ulevitch has an AB from Washington and Jefferson College and a PhD in Biochemistry from the University of Pennsylvania.

Dr. Forrest joined 5AM Ventures in 2005 from Princeton University where he completed his graduate work on RNA-based regulatory processes in the lab of Dr. Elizabeth Gavis. Dr. Forrest currently serves as a board observer to 5AM portfolio companies including Marcadia Biotech, Pulmatrix Inc., Relypsa Inc., SteriCoat Inc., Variation Biotechnologies, Inc. and WaveRx, Inc. Dr. Forrest holds a BS in Biology with honors from Boston College and a PhD in Molecular Biology from Princeton University. Dr. Forrest is based in 5AM's Waltham, MA office.

Dr. McMillan joined 5AM Ventures in 2005 from the National Aeronautics and Space Administration (NASA), where he was a Principal Investigator in the Bioengineering Branch and member of the Center for Nanotechnology at the Ames Research Center. Dr. McMillan currently serves as a board observer to 5AM portfolio companies including Achaogen Inc., Ambrx Inc., Antipodean Pharmaceuticals Inc., KaloBios Inc., Pearl Therapeutics Inc., and Wildcat Discovery Technologies, Inc. Dr. McMillan earned a BS in Chemistry from University of North Carolina-Chapel Hill and a PhD in Chemistry from Emory University, where he was awarded department honors for his research in biomaterials for drug delivery and tissue engineering. Dr. McMillan is based in 5AM's Menlo Park, CA office.

About 5AM Ventures

Founded in 2002, 5AM Ventures makes seed and early-stage investments in next-generation life science companies. Formed by successful industry executives and veteran venture capitalists, the 5AM team takes a focused, hands-on approach to company building. The 5AM portfolio is diversified among innovative platforms, spinouts from established biotechnology and pharmaceutical companies, and companies developing near-term products. With over $200 million under management, 5AM has invested in more than 20 companies during the past five years and is actively investing 5AM Ventures II, a $150 million fund. For more information on 5AM Ventures, please visit http://www.5amventures.com.


'/>"/>
SOURCE 5AM Ventures
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Hank Plain Joins Morgenthaler Ventures as Partner
2. Dan Broderick Joins Prolog Ventures as Partner
3. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
4. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
5. Khosla Ventures and BIOeCON Form KiOR Inc.
6. Jerusalem Global Ventures Announces $200 Million Growth Equity Fund
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... (March 29, ... Mexico has been approved as an active member of the Mexican Direct ... among distributers and consumers in relationship marketing. This professional organization fosters loyal and ...
(Date:3/29/2017)... DIEGO , March 29, 2017  Halozyme ... novel oncology and drug-delivery therapies, today announced that ... Food and Drug Administration voted 11 to 0 ... the skin) injection was favorable for patients in ... B-cell lymphoma and chronic lymphocytic leukemia. The FDA ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... it is exhibiting in booth 513 at the Association of Community Cancer Centers ... Hotel, March 29-31. , CANCERSCAPE unites key stakeholders from leading national organizations ...
(Date:3/29/2017)... NEWARK, Del. , March 29, 2017 ... medicine company, and W. L. Gore & ... announced a collaborative research agreement whereby the two companies ... delivery device technologies that provide protection from immune rejection. ... has been developing innovative stem cell-derived cell replacement therapies ...
Breaking Biology Technology:
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , ... software globally, announces significant enhancements to new and core ... 2016. New products include mobile and desktop Acuant FRM ... TM - a real time manual review of ... idScan® technology provides the fastest and most accurate capture ...
(Date:2/26/2017)... 25, 2017  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announces the ... "Too often, too many offenders return ... jails are trying to tackle this ongoing problem ... and family members. While significant steps are underway, Securus ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
Breaking Biology News(10 mins):